DICE Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About DICE Therapeutics, Inc.

DICE Therapeutics, Inc. was a U.S.-based biopharmaceutical company focused on discovering and developing novel oral therapies for inflammatory and immunology diseases. Before being acquired, it was listed on the NASDAQ and headquartered in South San Francisco, California, a core biotechnology cluster in the United States. The company evolved from DiCE Molecules Holdings, LLC into DICE Therapeutics, Inc. in connection with its IPO, and its business was built around a proprietary discovery engine called DELSCAPE, designed to identify selective oral small molecules capable of modulating protein-protein interactions with biologic-like potency. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm?utm_source=openai)) From an operating perspective, DICE was a clinical-stage biotech rather than a commercial-stage pharmaceutical company. It did not have approved products or product revenue at the time it operated independently. Its lead strategic focus was on oral IL-17 inhibitors, an important validated target in immunology. That positioning was commercially attractive because the company was trying to address a major market need: offering oral alternatives to injectable biologics, potentially improving convenience, adherence, and patient access. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1645569/000156459021056499/dice-10q_20210930.htm?utm_source=openai)) Competitively, DICE stood out for applying small-molecule chemistry to targets often dominated by antibodies and other biologics. This differentiated platform was its key asset and also the basis for its investment case. At the same time, the company carried the typical risks of an early- and mid-stage biotech: substantial operating losses, dependence on external capital, and a pipeline whose value depended on clinical success, regulatory progress, and eventual commercialization. SEC filings indicate that the company had accumulated significant losses during development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1645569/000095017023021193/dice-20230331.htm?utm_source=openai)) The most important recent development was the company’s acquisition by Eli Lilly. In June 2023, Lilly announced a definitive agreement to acquire DICE for about $2.4 billion, highlighting DICE’s oral immunology pipeline and technology platform. Lilly completed the acquisition on August 9, 2023. For investors reviewing Form 4 insider transaction data or historical SEC filings, the key point is that DICE Therapeutics no longer exists as an independent public company today; it was integrated into Lilly, although its legacy filings remain on the SEC record. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-dice-therapeutics-advance-innovation-immunology?utm_source=openai))